Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Deutsches Krebsforschungszentrum

Dennis Kirchhoff

Hans-Georg Lerchen

Anne-Sophie Rebstock

Beatrix Stelte-Ludwig

Stephan Märsch

Simone Greven

Christoph Mahlert

Yolanda Cancho Grande

Lisa Dietz

Sven Wittrock

Sandra Berndt

Stefanie Hammer

Benjamin Bader

Norbert Schmees

Nicolas Werbeck

Kirstin Petersen

Anette Sommer

Rienk Offringa

Mareike Grees

Ulf Bömer

Dirk Kosemund

Christina Kober

Christian Lechner

Lars Wortmann

Thi Thanh Uyen Nguyen

Ulf Boemer

Corinna Link

Ulrike Roehn

Katrin Nowak-reppel

Detlef Stoeckigt

Giambattista Testolin

Ulrich Rosentreter

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminoquinolones as DGKalpha inhibitors for immune activation

The present invention covers aminothiazole compounds of general formula (I), in which R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase zeta (DGKζ) regulated disorders, as a sole agent or in combination with other active ingredients.

Substituted aminothiazoles as DGKzeta inhibitors for immune activation

The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.

Antibody drug conjugates (ADCs) having enzymatically cleavable groups

The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies

Antibody drug conjugates (ADCS) having enzymatically cleavable groups

Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.

Specific antibody drug conjugates (ADCs) having KSP inhibitors

The invention relates to specific Antibody-Drug-Conjugates (ADCs) with KSP inhibitors and anti-CD 123-antibodies, to the use of these conjugates for the treatment and/or prophylaxis of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be carried out as monotherapy or else in combination with other medicaments or further therapeutic measures.

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies

Growing community of inventors

Berlin, Germany

Dennis Kirchhoff